ABBV Options Signal Bullish Momentum: Key Strikes and Trade Setups for Feb 6, 2026

• ABBV surges 2.23% to $223.92, breaking above 30D SMA but still below 100D SMA.
• Options data shows heavy call open interest at $230–$235 strikes, with a block trade hinting at March 2026 bullish bets.
• Moody’s upgrade and Skyrizi/Rinvoq momentum fuel analyst optimism, but debt and patent risks linger.

Here’s the thing: ABBV’s options market is screaming upside potential right now. Calls at $230 and $235 dominate open interest, while the stock trades near its intraday high. But let’s dig deeper—this isn’t just a short-term pop. It’s a setup.

Bullish Sentiment Locked in OTM Calls, But Puts Signal Caution

The options chain tells a clear story. For Friday’s expiration, ABBV20260213C230 and ABBV20260213C235 have 2,101 and 677 open contracts respectively—nearly 30% of total call OI. That’s heavy money betting on a push above $230. Meanwhile, puts at $222.5 (1,083 OI) and $200 (657 OI) suggest some hedging against a pullback. The put/call ratio (0.92) is nearly balanced, but the skew toward higher strikes shows conviction in the upside.

Don’t ignore the block trade: ABBV20260313C235 saw 915 contracts traded, totaling $266k. Someone’s locking in a March 2026 target. That’s not noise—it’s a signal. But here’s the catch: If ABBV fails to hold above $219.99 (middle Bollinger Band), those bullish bets could unravel.

News Flow: Why Analysts Are Bullish (But Not All-In)

Moody’s just upgraded ABBV to A2, praising its "above-peer earnings growth" despite Humira’s patent cliff. That’s a big deal for institutional buyers. Analysts at UBS, Citi, and Cantor Fitzgerald all have $230+ price targets, citing Skyrizi and Rinvoq’s momentum. The Phase 1 on-body injector trial for Skyrizi? That’s real-world convenience that could boost adoption.

But here’s the tension: Corcept’s ovarian cancer drug and AbbVie’s $70B debt load are shadows over the rally. The stock’s 53 RSI isn’t overbought yet, but it’s creeping toward 55—so a pullback isn’t out of the question.

Actionable Trades: Calls, Breakouts, and Price Targets

For options traders: ABBV20260213C230 is your best bet this week. If ABBV closes above $225.82 (intraday high), this call could pop. For next Friday, ABBV20260220C225 offers a cheaper premium with a lower strike, ideal if the stock consolidates. Avoid the $240 calls—they’re too far out.

Stock traders: Look to enter near $224 if support at $219.99 holds. First target: $227 (break above 30D SMA). Second: $230 (key call strike). Stop-loss below $218.50 (intraday low) would force a reevaluation.

Volatility on the Horizon: Balancing Bullish Bets and Risks

ABBV isn’t just a one-way bet. The Bollinger Bands show a tight range between $213 and $227—so a breakout either way could trigger sharp moves. With the 200D SMA at $209.40 still far below current price, the long-term trend remains neutral. But for the next two weeks, the options market and news flow are clearly tilted bullish.

Bottom line: This is a high-conviction trade for those willing to ride the Skyrizi/Rinvoq wave. But keep an eye on that $219.99 level—it’s the thin line between a breakout and a breakdown. Play it smart, and let the data guide your exit when the momentum fades.